Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01798706) enrolled 350 people with type 2 diabetes — 176 in the lixisenatide group and 174 in the placebo group. Around 155 and 153 people respectively completed the study. The trial ran for 24 weeks and was primarily measuring changes in HbA1c, which is a blood test that reflects average blood sugar levels over roughly three months. A number of secondary measurements were also tracked, including blood sugar levels after a meal, fasting blood sugar, body weight, and how many participants needed extra (rescue) medication during the study. The reported data shows that, on average, HbA1c fell by 0.57 percentage points in the lixisenatide group, compared with a rise of 0.06 percentage points in the placebo group. For blood sugar measured two hours after eating, the lixisenatide group showed an average reduction of 5.12 mmol/L, while the placebo group showed almost no change (−0.07 mmol/L). A broader daily blood sugar measure (average of seven readings across the day) fell by 1.15 mmol/L in the lixisenatide group versus 0.19 mmol/L in the placebo group. Fasting blood sugar dropped by 0.3 mmol/L with lixisenatide and was essentially unchanged with placebo. Body weight fell on average by 1.47 kg in the lixisenatide group and 0.16 kg in the placebo group. The reported data also shows that approximately 2.9% of participants in the lixisenatide group needed rescue medication during the 24 weeks, compared with 10.4% in the placebo group. These numbers reflect what was recorded and reported in this specific trial under its particular conditions, and do not necessarily represent what any individual person might experience. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Type 2 Diabetes Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are aged 70 years or older and have been diagnosed with type 2 diabetes that is not well controlled with your current diabetes medications
- You are willing and able to sign a consent form agreeing to take part in the trial
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- Your blood sugar control reading (HbA1c) is either very well controlled (at or below 7.0%) or very poorly controlled (above 10%) at the screening visit
- You are currently taking both a basal (long-acting) insulin and a certain type of diabetes pill called a sulfonylurea or meglitinide at the same time
- Your fasting blood sugar level is above 250 mg/dL at the screening visit
- You have type 1 diabetes, or have had a serious diabetes-related emergency called ketoacidosis in the past year
- You were diagnosed with type 2 diabetes less than one year ago
- Your current diabetes treatment has recently changed or was started within the last 3 months
- You have taken certain diabetes medications not listed as allowed in this trial within the past 3 months (confirm with trial site for the full list of permitted medications)
- You have ever taken a GLP-1 medication such as exenatide, liraglutide, or lixisenatide (or similar drugs)
- You have had a severe low blood sugar episode in the past 6 months that caused you to be unaware of symptoms, lose consciousness, fall into a coma, or have a seizure
- Your body mass index (a measure of body weight relative to height) is below 22 or above 40
- You are assessed by the study doctor as being malnourished, or you score below 12 on a standard nutrition questionnaire
- You have been assessed as having a cognitive disorder or dementia, score below 24 on a standard memory and thinking test, or have any nerve or brain condition that would affect your ability to take part in the study
- Your kidneys are not working well enough, based on a specific measurement of kidney function (confirm with trial site)
- You have a serious or uncontrolled illness, or any significant finding on physical examination that the study doctor believes would make it unsafe for you to participate
- Certain blood test results at screening are abnormal, including raised levels of pancreas-related enzymes (amylase and/or lipase), liver enzymes (ALT or AST), or a hormone called calcitonin
- You have or have had significant stomach or digestive problems involving long-lasting nausea and vomiting, such as gastroparesis or poorly controlled acid reflux, within the past 6 months
- You have a history of unexplained or chronic pancreatitis, have had your pancreas or part of your stomach removed, or have inflammatory bowel disease
- You or a close family member have a history of a specific type of thyroid cancer called medullary thyroid cancer, or a genetic condition that increases the risk of it
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Clinical Sciences & Operations, Sanofi
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 6 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Absolute Change in HbA1c From Baseline to Week 24
Other options
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.